Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.65B
Revenue (ttm)	714.73M
Net Income (ttm)	145.49M
Shares Out	57.35M
EPS (ttm)	2.51
PE Ratio	11.45
Forward PE	9.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	919,723
Open	29.31
Previous Close	29.53
Day's Range	27.72 - 29.59
52-Week Range	26.47 - 41.61
Beta	0.80
Analysts	Strong Buy
Price Target	54.00 (+87.83%)
Earnings Date	Apr 29, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 268
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2024, HRMY's revenue was $714.73 million, an increase of 22.80% compared to the previous year's $582.02 million. Earnings were $145.49 million, an increase of 12.91%.

Analyst Forecast

According to 8 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price forecast is $54.0, which is an increase of 87.83% from the latest price.

Price Target

$54.0

(87.83% upside)

Analyst Consensus: Strong Buy